Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.O)

ALNY.O on Nasdaq

65.49USD
22 Jul 2016
Change (% chg)

$0.52 (+0.80%)
Prev Close
$64.97
Open
$65.24
Day's High
$65.85
Day's Low
$64.58
Volume
770,778
Avg. Vol
923,305
52-wk High
$136.28
52-wk Low
$49.96

ALNY.O

Chart for ALNY.O

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational... (more)

Overall

Beta: 2.51
Market Cap(Mil.): $5,589.92
Shares Outstanding(Mil.): 85.36
Dividend: --
Yield (%): --

Financials

  ALNY.O Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -4.03 -- --
ROI: -24.46 -5.86 14.35
ROE: -25.49 -4.70 15.56

BRIEF-Alnylam initiates Phase 1/2 clinical trial for ALN-HBV

* Alnylam initiates phase 1/2 clinical trial for ALN-HBV, an investigational RNAI therapeutic for the treatment of chronic Hepatitis B virus infection

Jul 07 2016

BRIEF-Alnylam Pharmaceuticals names David-Alexandre Gros Principal Financial Officer

* Appointed David-Alexandre Gros, M.D. Senior VP and chief business officer to serve as principal financial officer

Jun 15 2016

BRIEF-Bioxcel Corp says begins collaboration with Alnylam to discover novel RNAi therapeutic products

* Begins strategic collaboration with Alnylam to discover novel RNAi therapeutic products;financial terms of agreement were not disclosed

May 24 2016

U.S. RESEARCH ROUNDUP-International Paper, United Technologies, Republic Services

May 3 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including On Deck Capital and Ceva, on Tuesday. HIGHLIGHTS * International Paper Co : Jefferies cuts to hold from buy * Republic Services Inc : Barclays raises to overweight from equal weight * SBA Communications Corp : JP Morgan cuts to neutral from overweight * Bill Barrett Corp : Deutsche Bank cuts to hold f

May 03 2016

BRIEF-Alnylam Pharmaceuticals reports Q1 GAAP loss per share $1.21 including items

* Q1 earnings per share view $-1.05 -- Thomson Reuters I/B/E/S

May 02 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.